Bristol-Myers Squibb Company Celegne Contingent Value Rights Bolsa (NYSE: CELGr)

Últimas noticias sobre Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGr) Bolsa

Bristol-Myers Squibb Company Celegne Contingent Value Rights

XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has surged 12% <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">over the past week</a>, fueled by a spike in whale transactions and a sharp increase in active addresses. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.48</td>
<td>$143.9 billion</td>
<td>+1.1%&nbsp;</td>
<td>+12.2%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2016</td>
<td>$29.9 billion</td>
<td>+2.5%&nbsp;</td>
<td>-0.4%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001315</td>
<td>$7.8 billion</td>
<td>+1.6%&nbsp;</td>
<td>-6.1%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Glauber Contessoto, the &#8216;<a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44005875/dogecoin-millionaire-shares-meme-coin-picks-leaving-everyone-else-in-the-dust-did-doge-shib-pepe-make-the-cut">Dogecoin millionaire</a>,&#8217; <a href="https://x.com/ProTheDoge/status/1897306846202863948">detailed</a> that he heavily accumulated XRP, Dogecoin and Cardano in 2022 and 2023 at rock-bottom prices: XRP at $0.40, Cardano at $0.24 and Dogecoin at $0.05. He describes these as &#8220;tried and true projects&#8221; and believes patience will pay off.  
Crypto analyst MartyParty <a href="https://x.com/martypartymusic/status/1897132301798281724">raised </a>concerns about XRP's valuation vs. its actual utility, pointing out that XRP processes 6x more transactions per second (7.84) than Cardano but remains 165x behind Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) in adoption. 
Despite XRP's massive $144.5 billion market cap, its network has not been tested at the scale needed to handle high trading volumes.
He warns that if put under stress, both XRP and Cardano could face a 90% collapse due to potential network failure. 
He also questions whether XRP and Cardano can function as true &#8220;Stores of Value&#8221; given their relatively weak node security compared to Bitcoin.
Since they are weak both as execution networks and as stores of value, he questions why their valuations remain so high, implying that their prices are propped up by speculation rather than real utility.
Statistics: Crypto chart analyst Ali Martinez highlighted a massive 620% spike in XRP active addresses over the past week, jumping from 74,589 to 462,650. 
Over $5.37 billion worth of XRP was <a href="https://x.com/ali_charts/status/1897213998501703914">moved</a> in the last 24 hours, with whales purchasing 1 billion XRP in a single day.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The number of active <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> addresses has skyrocketed by 620% in the past week, climbing from 74,589 to 462,650! <a href="https://t.co/eesFlnJw24">pic.twitter.com/eesFlnJw24</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1897091189125386302?ref_src=twsrc%5Etfw">March 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Altcoin Buzz <a href="https://x.com/Altcoinbuzzio/status/1897228166126850318">stated</a> that German's largest bank Dekabank is looking at Ripple for its crypto services.
Community News: Ripple CTO David Schwartz <a href="https://x.com/JoelKatz/status/1897173111029817546?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1897173111029817546%7Ctwgr%5E58ede01387631c15e17c1aa4e40d3ef2ac7d6aa3%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fu.today%2Fripple-cto-ends-speculation-on-xrp-supply-details">reacted</a> on a X banter between VP, Research at Riot Platforms and a crypto trader who assumed that XRP Ledger has a secret mint button to create an XRP. Schwartz shut down speculation on X (formerly Twitter) that the XRP Ledger has a hidden mint function, confirming that no network rule allows new XRP creation.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44127107/eric-trump-says-timing-of-strategic-bitcoin-xrp-cardano-reserve-announcement-was-a-win-for">Eric Trump Says Timing Of Strategic Bitcoin, XRP, Cardano Reserve Announcement Was A &#8216;Win&#8217; For Retail Investors</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$ADA

$DOGE

$SHIB

$SOL

$XRP

'Dogecoin Millionaire' Says He's Been Accumulating XRP Since $0.40

Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) stock is moving lower on Wednesday. Weakness in the stock may be due to President Donald Trump&#8216;s call to end the <a href="https://www.benzinga.com/media/25/02/44052935/intel-delays-28-billion-ohio-chip-plant-again-pushing-opening-to-2030-amid-financial-struggles">CHIPS and Science Act</a>.
What To Know: Trump, during his address to Congress on Tuesday, called for an end to the CHIPS Act, stating, "your Chips Act is a horrible, horrible thing,&#8221; according to <a href="https://www.bloomberg.com/news/articles/2025-03-05/trump-calls-for-end-to-52-billion-chips-act-subsidy-program?embedded-checkout=true">Bloomberg</a>.
The CHIPS Act allocated $39 billion in grants and loans, along with 25% tax breaks, to boost U.S.-based semiconductor manufacturing. It also dedicated $11 billion for chip research and development. 
The goal of the law was to lower dependence on Asian suppliers for critical electronic parts. Trump criticizes it as wasteful, suggesting tariffs could achieve similar results while generating revenue.
Intel received up to $7.86 billion in CHIPS Act funding for its semiconductor factory building efforts, according to <a href="https://www.cnbc.com/2024/11/25/intel-close-to-8-billion-chips-act-grant-source.html#:~:text=Intel%20and%20the%20Commerce%20Department,support%20Intel's%20chip%20manufacturing%20expansion.">CNBC</a>. The company is investing billions of dollars into these efforts, but its Ohio-based factory opening has been delayed until the early 2030s.
Investors may be reacting negatively as an end to the act could threaten Intel&#8217;s plans.
See Also: <a href="https://www.benzinga.com/25/03/44147370/taiwan-semiconductor-caught-between-us-tariff-threats-and-taiwans-push-to-keep-advanced-chip-tech">Taiwan Semiconductor Caught Between US Tariff Threats and Taiwan&#8217;s Push To Keep Advanced Chip Tech</a>
INTC Price Action: At the time of writing, Intel shares are trading 4.03% lower at $20.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Movers

INTC

What's Going On With Intel Shares Wednesday?

On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) shares traded higher on Wednesday. Multiple firms raised their respective price forecasts for the stock.
<ul>
<li>Telsey Advisory Group analyst Cristina Fernández reiterated the Outperform rating on On Holding, with a price forecast of $67.</li>
<li>Needham analyst Tom Nikic maintained the Buy rating on the stock, with a price forecast of $64.</li>
<li>Raymond James analyst Rick B. Patel reiterated the Strong Buy rating on the company, with a price forecast of $68.</li>
</ul>
Telsey Advisory Group: The analyst expresses confidence in On&#8217;s ability to meet or surpass its 2025 guidance, citing its manufacturing base in Vietnam and minimal exposure to Chinese import tariffs.
Per Fernández, On is on track to meet its 2026 financial targets, with apparel growth showing positive momentum due to new retail stores and marketing campaigns featuring Zendaya and FKA Twigs.
The analyst stresses that On can continue its brand momentum in 2025 through key initiatives, including product launches, new store openings, wholesale growth, increased apparel penetration, and ongoing marketing campaigns.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44070799/mark-cuban-supports-trumps-new-gold-card-scheme-if-sold-to-corporations-for-employee-citizenship-have-a-look-at-the-listed-companies-with-most-number-of-immigrants" rel="noreferrer noopener">Mark Cuban Supports Trump's New ‘Gold Card' Scheme If Sold To Corporations For Employee Citizenship: Here're The Listed-Companies With Most Number Of Immigrants</a>
Needham: The analyst highlights that On has gained significant popularity among Gen Z consumers, with a notable increase in product sales to those under 35, likely driven by high-profile collaborations with Zendaya and FKA Twigs.
Per Nikic, the company has a continued runway for strong growth, as they grow brand awareness and gain shelf space with the largest and best sneaker retailers in the world.
Raymond James: Patel notes that On is improving its e-commerce apparel presentation and integrating apparel with brand ambassadors to boost growth, positioning itself as a lifestyle brand, not just a footwear one.
The analyst updated the 2025/2026 estimates based on fourth-quarter earnings and the new guidance.
Revenue is projected to grow by 29% in 2025 and 22% in 2026. EBITDA margin is expected to be 17.4% in 2025 and 18.1% in 2026. Previously, the estimates were 29%/22% for revenue and 17.1%/17.4% for EBITDA margin.
Price Action: ONON shares are trading higher by 5.25% to $53.29 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44141064/stratasys-beats-q4-earnings-estimates-ceo-eyes-120-million-investment-to-drive-future-growth" target="_blank" rel="noreferrer noopener">Stratasys Beats Q4 Earnings Estimates, CEO Eyes $120 Million Investment To Drive Future Growth</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Equities

Price Target

Reiteration

Markets

Analyst Ratings

Trading Ideas

General

ONON

On Holding's Growth Soars: Analysts See Strong Upside Amid New Initiatives Beyond Footwear, Star-Studded Marketing

The once-unshakable dominance of the <a href="https://www.benzinga.com/topic/magnificent-seven">Magnificent Seven</a> (or Mag 7) stocks is under scrutiny.
Stretched valuations and artificial intelligence investment concerns are weighing on mega-cap tech. The Bloomberg Mag Seven Index, an equal-weighted basket of these high-flyers, has officially entered correction territory. It&#8217;s down 10% year-to-date, notes Adam Turnquist, Chief Technical Strategist at LPL Financial.
<h2 class="wp-block-heading">Technical Breakdown: Key Support Levels Under Threat</h2>
According to Turnquist, the group has violated a key uptrend from October 2023 and is now testing critical support at the 200-day moving average. A breakdown from here could open the door to deeper losses, potentially revisiting last August's highs or lows. 
Meanwhile, the Magnificent Seven's relative strength versus the equal-weight S&amp;P 500 is also at a pivotal juncture—if support doesn't hold, Turnquist warns that their leadership status may be in jeopardy.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/03/44101332/sp-500-selloff-spikes-investor-pessimism-bearish-sentiment-hits-30-month-high-but-this-expert-recommends-investors-to-stay-strong-and-not-panic-sell" target="_blank" rel="noreferrer noopener">S&amp;P 500 Selloff Spikes Investor Pessimism: Bearish Sentiment Hits 30-Month High, But This Expert Recommends Investors To ‘Stay Strong And Not Panic Sell'</a>
<h2 class="wp-block-heading">MAGS ETF Signals Strong Bearish Momentum</h2>
The Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), a fund tracking the group, is reflecting the broader weakness. MAGS is down 8.07% year-to-date and 9.29% in the past month.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05135348/Screenshot-2025-03-06-at-12.23.34-AM.png" alt="" class="wp-image-810810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05135348/Screenshot-2025-03-06-at-12.23.34-AM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05135348/Screenshot-2025-03-06-at-12.23.34-AM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technicals paint a bleak picture, with the stock trading below its eight-day, 20-day and 50-day simple moving averages, signaling strong bearish momentum. 
However, some buying pressure is emerging, with the 200-day simple moving average at $48.76 acting as potential support.
<h2 class="wp-block-heading">The China Factor: AI Competition Heats Up</h2>
Adding to the uncertainty is China's DeepSeek AI platform, which raises fresh questions about whether American tech giants can maintain their AI supremacy. 
With earnings growth facing new challenges as these companies shift from asset-light to asset-heavy models, investors are left wondering: Is this just a pullback, or has the Mag Seven's reign finally run its course?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44105284/from-mag7-to-meh7-no-tech-giant-ranks-among-sp-500s-top-50-performers-in-2025-experts-say-struggle-is-justified">From &#8216;Mag7 To Meh7:&#8217; No Tech Giant Ranks Among S&amp;P 500&#8217;s Top 50 Performers In 2025, Experts Say &#8216;Struggle… Is Justified&#8217;</a></li>
</ul>
Image: Shutterstock

Broad U.S. Equity ETFs

Specialty ETFs

Technicals

Tech

ETFs

MAGS

Magnificent Seven Leadership In Question As MAGS ETF Stumbles: Is AI Losing Steam?

WIIM

ON Holding shares are trading higher on possible continued strength after the company reported better-than-expected Q4 financial results yesterday. Additionally, multiple firms raised their respective price targets on the stock.

DoubleLine has introduced the DoubleLine Asset-Backed Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DABS#NYSE">DABS</a>), an <a href="https://www.benzinga.com/etfs">actively managed fund</a> targeting long-term total return and current income. The fund, which launched on Tuesday, has a net expense ratio of 39 basis points and primarily invests in investment-grade asset-backed securities (ABS), though it may also hold unrated or high-yield fixed-income securities.
DABS invests in various ABS, including collateralized debt obligations and bond obligations. The fund's active management approach aims to adjust portfolio duration, expected to range between one and six years, to mitigate interest rate risk.
DoubleLine's ABS team <a href="https://www.prnewswire.com/news-releases/doubleline-asset-backed-securities-etf-lists-on-nyse-arca-exchange-302390997.html">manages </a>$4.7 billion across multi-sector portfolios.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/03/44146738/goldmans-new-buffer-etf-offers-fresh-protection-against-market-swings">Goldman&#8217;s New Buffer ETF Offers Fresh Protection Against Market Swings</a>
Expanding ETF Offerings
DABS is DoubleLine's eighth ETF in the U.S., contributing to a fund suite managing over $1.3 billion in assets, noted etftrends.com. 
The launch comes at a time when DoubleLine CEO and Chief Investment Officer Jeffrey Gundlach has <a href="https://www.bloomberg.com/news/articles/2024-09-17/gundlach-sees-a-half-point-rate-cut-with-fed-behind-the-curve">pointed </a>to a significant shift in the economic and financial scenario. "The economy and financial markets have entered a new secular environment that challenges previous wisdom on items such as traditional recession indicators," he said in January.
Gundlach highlighted a transition from "secular declining interest rates" to "secular rising interest rates, at least on the long end." He noted that "some of the traditional recession indicators don&#8217;t work, haven&#8217;t been working because they&#8217;ve worked during a different secular regime."
More broadly, Gundlach has spoken about structural shifts in the economy, describing what he calls the "fourth turning," a period of societal upheaval. "I feel like we're leaving the bus right here in the fourth turning."
With this latest ETF, DoubleLine continues to adapt to a changing market environment, offering investors access to specialized fixed-income strategies that align with shifting macroeconomic trends.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44144570/3-cybersecurity-etfs-in-focus-amid-reports-of-us-cyber-operations-suspension">3 Cybersecurity ETFs in Focus Amid Reports of US Cyber Operations Suspension</a></li>
</ul>
Photo: janews/Shutterstock.com

New ETFs

DABS

Jeffrey Gundlach's Latest ETF Aims To Leverage Rising Rate Environment

Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) issued its third-quarter earnings report on Tuesday. It <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44127539/credo-technology-stock-rallies-after-better-than-expected-q3-report-details" rel="noreferrer noopener">reported quarterly earnings</a> of&nbsp;25&nbsp;cents per share. It beat the analyst consensus estimate of&nbsp;18&nbsp;cents.
Quarterly revenue came in at $135 million (over revenue of $53.05 million a year ago) versus the analyst consensus estimate of&nbsp;$120.06 million.
Credo expects fourth-quarter revenue of&nbsp;$155M million-$165 million, versus the&nbsp;consensus estimate of $137.43 million.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44127539" rel="noreferrer noopener">Credo Technology Stock Rallies After Better-Than-Expected Q3 Report: Details</a>
Several Wall Street analysts rerated Credo stock:
<ul>
<li>Needham analyst Quinn Bolton reiterated Credo with a Buy and a <a href="https://www.benzinga.com/quote/CRDO/analyst-ratings" target="_blank" rel="noreferrer noopener">$80 price target</a>.</li>
<li>Roth MKM analyst Sujeeva De Silva maintained a Buy rating on Credo with a price target of $80.</li>
<li>Susquehanna analyst Christopher Rolland reiterated Credo with a Neutral and lowered the price target from $80 to $60.</li>
</ul>
Needham: Credo reported a significant revenue beat (+16% above Bolton&#8217;s estimate) and raise (+20% above his estimate) driven by growth at its largest hyperscaler customer, Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), which accounted for 86% of revenue in the third quarter of fiscal 2025, up +388% sequentially.
Management expects Amazon&#8217;s revenue to be in the same ballpark in the fourth quarter of fiscal 2025 (Bolton modeled ~$105 million) but sees other customers accounting for ~33% of revenue. As such, different customers will drive the +19% sequentially increase in the fourth quarter of 2025.
Credo reported another strong beat and guided revenue of $27 million (+20%) above Bolton&#8217;s estimate, driven by a stronger-than-expected ramp at its largest customer, Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Bolton highlighted that Amazon&#8217;s ramp is more substantial than anticipated, and he meaningfully raised his Amazon shipment estimates for fiscal 2026 and 2027. Amazon represented 86% of third-quarter revenue.
The company expects its customer base to diversify starting in the fourth quarter and continuing through fiscal 2026, with 3-4 customers likely reaching the 10% threshold.
The company&#8217;s PCIe retimer product line was certified by the PCIe SIG and won an ODM AI platform commitment with revenue expected in calendar 2026. The company will demonstrate PCIe AECs for scale-up networks at GTC.
Bolton also noted the management reiterated &gt;50% growth in fiscal 2026 (against Bolton&#8217;s +62%), despite the more decisive than anticipated second half of fiscal 2025.
Management expects the business to diversify going forward as 3-4 hyperscaler customers could be above 10% of sales in the fourth quarter of fiscal 2025 and into fiscal 2026.
The company has ramped AECs at three hyperscalers to date (Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>), Amazon, and xAI) and is in qualification with two additional hyperscalers who will likely ramp in fiscal 2026.
Bolton noted the fifth hyperscaler will begin deploying AECs for the first time in fiscal 2026. Management stated one of its hyperscalers, he expects as xAI, is receiving meaningful GPU allocations from Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), so he expects a strong revenue ramp at xAI in fourth-quarter of fiscal 2025 and fiscal 2026.
Management also stated that it expects its first hyperscaler customer, Microsoft, to ramp back to a $100 million annualized run rate in fiscal 2026.
Roth MKM: Credo reported results ahead of consensus and guided revenue well ahead of consensus, reflecting lead customer cabling program strength as well as the ramp of large customer programs in the coming quarters.
De Silva expects Cedo to benefit from its leadership position here as AI infrastructure continues to ramp and evolve to create additional connectivity content opportunity for the company across an expanding base of hyperscale customers.
Price Action: CRDO stock was down 15.4% at $45.87 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44149088/disney-cuts-200-jobs-across-abc-and-tv-networks-amid-restructuring" target="_blank" rel="noreferrer noopener">Disney Cuts 200 Jobs Across ABC News And Disney Entertainment Networks: Report</a></li>
</ul>
Image via Shutterstock

AMZN

CRDO

MSFT

NVDA

Analysts Highlight Credo Hyperscaler Partnerships With Amazon, Microsoft, xAI Amid AI Boom

Investors with a lot of money to spend have taken a bearish stance on Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FTNT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Fortinet.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 54%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $663,001, and 2 are calls, for a total amount of $72,354.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $100.0 for Fortinet over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Fortinet stands at 585.75, with a total volume reaching 16,657.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Fortinet, situated within the strike price corridor from $80.0 to $100.0, throughout the last 30 days.
<h3>Fortinet Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741202216_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.6</td>
<td>$5.55</td>
<td>$5.61</td>
<td>$100.00</td>
<td>$122.2K</td>
<td align="right">91</td>
<td>2.7K</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.7</td>
<td>$5.65</td>
<td>$5.68</td>
<td>$100.00</td>
<td>$96.5K</td>
<td align="right">91</td>
<td>3.4K</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$5.7</td>
<td>$5.3</td>
<td>$5.63</td>
<td>$100.00</td>
<td>$80.4K</td>
<td align="right">91</td>
<td>2.4K</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.55</td>
<td>$5.5</td>
<td>$5.53</td>
<td>$100.00</td>
<td>$71.8K</td>
<td align="right">91</td>
<td>2.5K</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.7</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$100.00</td>
<td>$70.5K</td>
<td align="right">91</td>
<td>917</td>
</tr>
</tbody>
</table>

<h3>About Fortinet</h3>
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
Following our analysis of the options activities associated with Fortinet, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Fortinet</h3>
<ul>
<li>With a volume of 2,383,472, the price of FTNT is up 0.23% at $106.72. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<h3>Professional Analyst Ratings for Fortinet</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $116.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Susquehanna persists with their Neutral rating on Fortinet, maintaining a target price of $110. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Fortinet, targeting a price of $105. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Fortinet, which currently sits at a price target of $115. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Hold rating for Fortinet, targeting a price of $115. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $135. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Fortinet options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

FTNT

Smart Money Is Betting Big In FTNT Options

DELL

Dell Technologies CFO Yvonne McGill Says: I Feel Strongly That The PC Refresh Cycle Will Not Be 100% Completed In This Year, It Will Extend Into Next Year-Morgan Stanley TMT Conference

Semiconductor giant Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) will be hoping to get back to a streak of beating analyst estimates for revenue and earnings per share when the company reports first-quarter financial results after <a href="https://www.benzinga.com/earnings">market close on Thursday.</a>
Here are the key analyst estimates and items to watch.
Earnings Estimates: Analysts expect Broadcom to report first-quarter revenue of $14.61 billion, up from $11.96 billion in last year's first quarter, according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company missed analyst estimates for revenue in the fourth quarter, while it has beaten estimates in eight of the last 10 quarters.
Analysts expect the company to report earnings per share of $1.49, up from $1.10 in last year's first quarter. The company missed estimates in the fourth quarter, while it has beaten analyst estimates in nine of the last 10 quarters overall.
Guidance <a href="https://www.benzinga.com/news/earnings/24/12/42472970/broadcom-reports-mixed-q4-results-eps-beat-revenues-miss-q1-guidance-in-line-with-estimates">from the company</a> calls for first-quarter revenue of $14.6 billion.
Read Also: <a href="https://www.benzinga.com/25/03/44076105/marvell-vs-broadcom-the-ai-arms-race-heats-up-ahead-of-earnings">Marvell Vs. Broadcom: AI Arms Race Heats Up Ahead Of Earnings</a>
Key Items to Watch: Broadcom recently unveiled VeloSky, a <a href="https://www.benzinga.com/25/03/44103223/broadcom-debuts-velosky-to-accelerate-5g-and-satellite-adoption">new networking solution</a> to enhance 5G and satellite services. Broadcom hopes the new product can help diversify and unlock new revenue.
The news follows Broadcom's partnership with Micron Technology <a href="https://www.benzinga.com/tech/25/02/43972821/broadcom-expands-ai-infrastructure-with-pcie-gen-6-partners-with-micron-for-seamless-integration">for AI infrastructure</a> expansion announced last month.
While these items are new for the current quarter and won't factor into first-quarter results, they could find their way into guidance for the current fiscal year and company commentary.
Another item to watch that Broadcom likely won't discuss in comments but could be asked about by analysts <a href="https://www.benzinga.com/markets/25/02/43761300/intel-could-be-split-in-two-as-broadcom-and-tsmc-explore-deals-trump-white-house-resists-foreign-ownership-report">is a report </a>that the semiconductor company is interested in acquiring portions of Intel Corp in a breakup.
A potential deal could see Broadcom getting Intel's chip design and marketing business with Taiwan Semiconductor getting Intel's chip plants.
Despite the fourth-quarter miss for revenue and earnings per share, Broadcom had several full fiscal year records including Semiconductor revenue hitting a record $30.1 billion driven by AI revenue of $12.2 billion.
Future guidance and commentary on the semiconductor industry could provide investors and analysts with an update on price targets and an outlook for the stock compared to peers.
Ahead of the earnings report, here are recent<a href="https://www.benzinga.com/quote/AVGO/analyst-ratings"> analyst ratings </a>and price targets on Broadcom stock:
<ul>
<li>Morgan Stanley: Maintained Overweight rating, lowered price target from $265 to $246</li>
<li>Barclays: Maintained Overweight rating, raised price target from $205 to $260</li>
<li>Mizuho: Maintained Outperform rating, raised price target from $245 to $260.</li>
</ul>
AVGO Price Action: Broadcom stock is up 2.5% to $192.25 on Wednesday versus a 52-week trading range of $119.76 to $251.87. Broadcom stock is down 17% year-to-date in 2025, while shares remain up 43% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43773352/stanley-druckenmiller-ditches-broadcom-ups-ante-on-big-tech">Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4</a></li>
</ul>

Previews

AVGO

Broadcom Q1 Earnings Preview: Semiconductor Looks To Get Back To Beating Analyst Estimates After Q4 Miss

MongoDB Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 66 cents in EPS and $519.60 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=MDB" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is down 37.60% over the past year, up 3.31% YTD.
Let&#8217;s look at what the charts indicate for Mongodb stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/03/44136446/mongodb-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">MongoDB Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
<h2 class="wp-block-heading">Mongodb Stock Strongly Bearish Ahead Of Q4 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05114321/Screenshot-2025-03-05-at-10.08.33-PM.png" alt="" class="wp-image-810592" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05114321/Screenshot-2025-03-05-at-10.08.33-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05114321/Screenshot-2025-03-05-at-10.08.33-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
MongoDB stock, at $253.40, is facing a strongly bearish trend, trading below its five-day, 20-day and 50-day exponential moving averages. The stock is also below key simple moving averages, with the eight-day at $261.47, 20-day at $276.70, 50-day at $262.53 and 200-day at $270.11 &#8211; all signaling continued downside pressure.
The Moving Average Convergence Divergence indicator at a negative 3.78 further reinforces the bearish sentiment, suggesting downward momentum remains intact.
However, there are signs of slight buying pressure, as indicated by the Relative Strength Index at 38.55. While still in bearish territory, RSI nearing 30 suggests the stock could be approaching oversold conditions, potentially setting up for a relief bounce.
Investors should watch for a break above key moving averages to confirm a shift in momentum, but until then, the technical outlook remains cautious.
<h2 class="wp-block-heading">MongoDB Analysts See 29% Upside</h2>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/MDB/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Mongodb stock stands at a Buy currently with a price target of $364.68. The latest ratings from Rosenblatt, Loop Capital and Scotiabank imply a 28.59% upside for MongoDB stock with a $325 target.
MDB Price Action: Mongodb stock was trading at $253 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44117207/mongodb-q4-preview-in-line-or-marginally-higher-results-expected-by-bullish-analyst">MongoDB Q4 Preview: In-line Or Marginally Higher Results Expected By Bullish Analyst</a></li>
</ul>
Image via Shutterstock

MongoDB Slides Into Q4 Earnings: Bearish Signals Vs. Wall Street Optimism

Macro Economic Events

Econ #s

Economics

Fed Beige Book: Overall Economic Activity Rose Slightly Since Mid-January; Overall Expectations For Economic Activity Over The Coming Months Were Slightly Optimistic; Prices Increased Moderately In Most Districts, But Several Districts Reported An Uptick

KMDA

Kamada shares are trading higher after the company reported better-than-expected Q4 EPS results and issued FY25 revenue guidance above estimates. Additionally, the company board approved a $0.20 per share special dividend.

Last week, Apellis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) reported a fourth-quarter earnings loss of 29 cents per share, beating the <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">consensus loss of 37 cents</a>. Sales increased 45.2% to $212.5 million, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $198.35 million</a>.
JP Morgan maintains the Overweight rating with a <a target="_blank" href="https://www.benzinga.com/quote/APLS/analyst-ratings" rel="noreferrer noopener">price forecast of $54</a>.
Analyst Anupam Rama says Apellis&#8217; lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset in the complement space, with opportunities across ophthalmology, hematology, neurology, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44038782/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">and nephrology indications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41366153/syfovres-competitive-edge-highlights-bright-future-for-apellis-pharmaceuticals-anal" rel="noreferrer noopener">Syfovre&#8217;s Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch</a>
The company generated Syfovre sales of $167.8 million and $611.9 million for the fourth quarter and full year 2024, respectively.
Delivered approximately 94,000 Syfovre doses to physician practices in the fourth quarter, including approximately 89,000 commercial vials and 4,600 samples. More than 510,000 Syfovre injections, including clinical trials, are estimated to have been administered since launch through December 2024.
JP Morgan views Syfovre as an over $1.5 billion peak potential drug, even with conservative assumptions.
&#8220;Overall, physicians continue to use the product, driving growth, and we anticipate a fundamental and sentiment shift driving upside in APLS shares,&#8221; the analyst writes.
Analyst Rama also expects that the Empaveli C3 glomerulopathy and primary immune complex glomerulonephritis (C3G/IC-MPGN) opportunity will be a driver for Apellis stock. The company has submitted a supplemental marketing application for approval of Empaveli based on Phase 3 VALIANT results at six months; if approved, a U.S. launch is expected in 2H 2025.
Price Action: APLS stock is up 3.27% at $25.87&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44143705/applovin-reportedly-selling-gaming-unit-to-tripledot-studios-in-900-million-deal" target="_blank" rel="noreferrer noopener">Applovin Reportedly Selling Gaming Unit To Tripledot Studios In $900-Million Deal</a></li>
</ul>

Biotech

Earnings

Health Care

APLS

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Investors with a lot of money to spend have taken a bullish stance on Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OKTA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Okta.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 22%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $25,900, and 8, calls, for a total amount of $437,188.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $120.0 for Okta over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Okta's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Okta's whale activity within a strike price range from $50.0 to $120.0 in the last 30 days. 
<h3>Okta Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741201281_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$22.95</td>
<td>$18.8</td>
<td>$20.53</td>
<td>$88.00</td>
<td>$102.6K</td>
<td>248</td>
<td>50</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$8.1</td>
<td>$7.3</td>
<td>$7.82</td>
<td>$105.00</td>
<td>$78.2K</td>
<td>1.1K</td>
<td>803</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.22</td>
<td>$105.00</td>
<td>$72.2K</td>
<td>1.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.35</td>
<td>$12.85</td>
<td>$13.35</td>
<td>$120.00</td>
<td>$53.4K</td>
<td>559</td>
<td>468</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$2.86</td>
<td>$2.54</td>
<td>$2.7</td>
<td>$108.00</td>
<td>$43.1K</td>
<td>574</td>
<td>258</td>
</tr>
</tbody>
</table>

<h3>About Okta</h3>
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Following our analysis of the options activities associated with Okta, we pivot to a closer look at the company's own performance.
<h3>Where Is Okta Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 6,195,054, with OKTA's price up by 4.42%, positioned at $113.1.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 84 days.</li>
</ul>
<h3>What Analysts Are Saying About Okta</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $117.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Susquehanna has decided to maintain their Neutral rating on Okta, which currently sits at a price target of $105. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Okta, targeting a price of $100. 
&#x2A; An analyst from WestPark Capital downgraded its action to Buy with a price target of $140. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Okta with a target price of $120. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Okta, maintaining a target price of $123. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Okta options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

OKTA

A Closer Look at Okta's Options Market Dynamics

Analysts' ratings for Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.9, along with a high estimate of $90.00 and a low estimate of $70.00. A decline of 4.15% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201265_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Carrier Global. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Nigel Coe</td>
<td>Wolfe Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Carrier Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Carrier Global compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Carrier Global's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Carrier Global's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CARR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Carrier Global analyst ratings.</a>
<h2>Unveiling the Story Behind Carrier Global</h2>
Carrier Global manufactures heating, ventilation, and air conditioning, refrigeration, and fire and security products. The HVAC business serves both residential and commercial markets (HVAC segment sales mix is 60% commercial and 40% residential). Carrier's refrigeration segment consists of its transportation refrigeration, Sensitech supply chain monitoring, and commercial refrigeration businesses. The firm's fire and security business manufactures fire detection and suppression, access controls, and intrusion detection products. In April 2023, Carrier announced that it plans to divest its fire and security and commercial refrigeration businesses. The firm also acquired Germany-based Viessmann for approximately $13 billion.
<h3>Key Indicators: Carrier Global's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Carrier Global's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.28% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 49.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Carrier Global's ROE excels beyond industry benchmarks, reaching 17.73%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Carrier Global's ROA stands out, surpassing industry averages. With an impressive ROA of 6.57%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.9, Carrier Global adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARR

Where Carrier Global Stands With Analysts

Throughout the last three months, 4 analysts have evaluated BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $3.88, a high estimate of $6.00, and a low estimate of $2.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 24.22%. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201255_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive BRC. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$3.50</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BRC. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of BRC compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BRC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of BRC's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRCC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BRC analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind BRC</h2>
BRC Inc is a veteran-controlled company that serves premium coffee, content, and merchandise to active military, veterans, and first responders. it is committed to producing great coffee that consumers love, and high-quality merchandise that enables its community to showcase its brand. its omnichannel distribution has three components: Direct to Consumer channel includes its e-commerce business, through which consumers order products online and products are shipped to them, Its wholesale channel includes products sold to an intermediary such as convenience, grocery, drug, and mass merchandise stores, who in turn sell those products to consumers, and Outpost channel includes revenue from its Company-operated and franchised Black Rifle Coffee retail coffee shop locations.
<h3>Key Indicators: BRC's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, BRC faced challenges, resulting in a decline of approximately -11.51% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: BRC's net margin excels beyond industry benchmarks, reaching -2.34%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BRC's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -17.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.08%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 7.34, BRC faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRCC

What Analysts Are Saying About BRC Stock

Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $26.25, along with a high estimate of $30.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 6.4% from the previous average price target of $24.67.
<img src="https://www.benzinga.com/files/images/story/2025/1741201247_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Oceaneering International's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Oceaneering International. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Oceaneering International compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Oceaneering International's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Oceaneering International's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oceaneering International analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Oceaneering International's Background</h2>
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
<h3>Oceaneering International's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Oceaneering International showcased positive performance, achieving a revenue growth rate of 8.99% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Oceaneering International's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.86% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.94%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Oceaneering International's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Oceaneering International's debt-to-equity ratio is below the industry average. With a ratio of 1.19, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Oceaneering International: What You Need To Know

4 analysts have shared their evaluations of NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.0, a high estimate of $20.00, and a low estimate of $14.00. This current average reflects an increase of 24.36% from the previous average price target of $13.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201236_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of NeuroPace among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeuroPace. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of NeuroPace compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NeuroPace's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NeuroPace's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NPCE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NeuroPace analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About NeuroPace</h2>
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
<h3>Unraveling the Financial Story of NeuroPace</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeuroPace displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 28.2%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NeuroPace's net margin excels beyond industry benchmarks, reaching -25.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -55.33%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): NeuroPace's ROA stands out, surpassing industry averages. With an impressive ROA of -5.72%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 7.48, NeuroPace faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NPCE

What 4 Analyst Ratings Have To Say About NeuroPace

4 analysts have expressed a variety of opinions on Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.39, a high estimate of $11.00, and a low estimate of $8.55. A decline of 5.55% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201225_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Chimerix among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.55</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chimerix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chimerix compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Chimerix's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chimerix's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CMRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chimerix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Chimerix's Background</h2>
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
<h3>Financial Insights: Chimerix</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Chimerix showcased positive performance, achieving a revenue growth rate of 136.36% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Chimerix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -87996.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chimerix's ROE excels beyond industry benchmarks, reaching -15.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Chimerix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Chimerix's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Bristol-Myers Squibb Company Celegne Contingent Value Rights

Noticias

Últimas noticias sobre Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGr) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL